Librela for dogs is designed to manage pain and inflammation associated with osteoarthritis in dogs. 

​

The active ingredient in Librela is bedinvetmab, which is a monoclonal antibody that selectively targets and neutralizes the action of nerve growth factor (NGF). NGF is a protein that plays a role in the transmission of pain signals in the spinal cord, and by inhibiting its action, librela (bedinvetmab) can reduce pain and inflammation in dogs with osteoarthritis. Specifically, arthritis pain in dogs is often associated with the release of NGF from damaged cells in arthritic joints. This release can then contribute to further inflammation and soreness.

​

Librela for dogs is administered once monthly as a subcutaneous injection. Generally, results will be seen within 7-28 days post-injection and peak at 60 days. If no response is realized after two treatments, other treatments should be taken into consideration.

Librela has been shown to provide several benefits for dogs suffering from osteoarthritis. One of the most significant benefits is a reduction in pain and inflammation, which can greatly improve a dog's quality of life.

​

Dogs treated with Librela have demonstrated increased mobility, allowing them to resume activities they may have previously been unable to do due to pain and stiffness. By reducing pain and inflammation, librela may also reduce the need for other medications that may have unwanted side effects, such as nonsteroidal anti-inflammatory drugs (NSAIDs).  But it can be used in combination with these and other medications. However, it is important to consult with your veterinarian before administering any medication to your dog.

​

Studies have proven that librela is effective in managing pain and inflammation in dogs with osteoarthritis, and it has been well-tolerated with few reported side effects. The use of Librela may also help prevent the progression of osteoarthritis in dogs by reducing inflammation and pain associated with the condition.

​

Considerations and Possible Reactions 

Librela is generally considered to be very safe for use in dogs with osteoarthritis. Uncommonly, injection site reactions such as swelling, and redness can occur but are usually mild and resolve without treatment within 1-2 days.

The use of librela in dogs is contraindicated in certain cases. It should not be used in dogs with hypersensitivity to the active substance or any of the ingredients.

​

Librela is not recommended for dogs under 12 months of age or for animals intended for breeding. It should also be avoided in pregnant or lactating animals, as the safety of the medication in these situations has not been established.

​

It is important to note that librela may induce transient or persistent anti-drug antibodies. While induction of such antibodies is uncommon, it may result in a decrease in efficacy in animals that responded to treatment previously.

Therefore, it is important to consult with a veterinarian before administering librela to your dog to ensure that it is safe and appropriate for your pet's individual situation.